Granules India Limited (NSE:GRANULES)
792.90
-6.30 (-0.79%)
Nov 11, 2026, 1:00 PM IST
Granules India Revenue
Granules India had revenue of 15.60B INR in the quarter ending September 30, 2026, with 20.28% growth. This brings the company's total for the last twelve months to 58.95B, up 21.75% year-over-year. In the fiscal year ending March 31, 2026, Granules India had annual revenue of 53.66B with 19.73% growth.
Revenue (ttm)
58.95B
Revenue Growth
+21.75%
P/S Ratio
3.35
Revenue / Employee
13.69M
Employees
4,306
Market Cap
195.91B
Revenue by Geography
- Outside India 51.44B 95.9%
- India 2.22B 4.1%
Fiscal year ended Mar 31, 2026 See the full Granules India breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 53.66B | 8.84B | 19.73% |
| Mar 31, 2025 | 44.82B | -247.59M | -0.55% |
| Mar 31, 2024 | 45.06B | -55.50M | -0.12% |
| Mar 31, 2023 | 45.12B | 7.47B | 19.84% |
| Mar 31, 2022 | 37.65B | 5.27B | 16.29% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Emcure Pharmaceuticals | 102.34B |
| Piramal Pharma | 97.79B |
| Alembic Pharmaceuticals | 84.77B |
| Ajanta Pharma | 62.17B |
| Akums Drugs and Pharmaceuticals | 48.29B |
| Wockhardt | 38.40B |
| NATCO Pharma | 34.85B |
| Eris Lifesciences | 33.12B |
Granules India News
- 8 days ago - Granules India Q2 net profit rises 39% - The Times of India
- 8 days ago - Granules India Transcript: Q2 26/27 - Transcripts
- 8 days ago - Granules India Quarterly report: Q2 2027 - Filings
- 8 days ago - Granules India Slides: Q2 2027 - Filings
- 5 weeks ago - Granules India plans ₹2,000 crore investment to drive growth in complex generics, oncology, and peptide CDMO - The Times of India
- 7 weeks ago - Hyderabad Granules promoter sells 7% stake to raise 1.5k crore - The Times of India
- 3 months ago - Granules India Transcript: Q1 26/27 - Transcripts
- 3 months ago - Granules India Quarterly report: Q1 2027 - Filings